ZNF530 Inhibitors
Chemical inhibitors of ZNF530 employ a variety of mechanisms to inhibit its function, primarily through the modulation of signaling pathways that control protein activity, phosphorylation states, and protein synthesis. Staurosporine, a broad-spectrum protein kinase inhibitor, can inhibit various kinases that are responsible for the phosphorylation of ZNF530, leading to a decrease in ZNF530's functionality. Similarly, LY294002 and Wortmannin, both specific inhibitors of phosphoinositide 3-kinases (PI3K), can reduce the phosphorylation of downstream signaling molecules, which in turn can affect the activity of ZNF530 by interrupting the cellular signaling processes that it is part of. Rapamycin, which inhibits mTOR, affects protein synthesis and cell growth, indirectly affecting the function of ZNF530 by disrupting essential cellular processes.
Further targeting specific signaling pathways, U0126 and PD98059 are selective inhibitors of MEK1/2, enzymes that are part of the MAPK/ERK pathway. By inhibiting these enzymes, they prevent the activation of ERK, which may be necessary for the phosphorylation and subsequent activity of ZNF530. SB203580, which inhibits p38 MAP kinase, and SP600125, which inhibits c-Jun N-terminal kinase (JNK), can decrease ZNF530's activity by interfering with stress response pathways and other signaling cascades involving these kinases. PP2, an inhibitor of Src family tyrosine kinases, can prevent the phosphorylation of substrates, including ZNF530, that are crucial for signal transduction processes. PD168393 and GW5074, which respectively inhibit EGFR tyrosine kinase and Raf-1 kinase, can disrupt downstream signaling pathways, potentially affecting ZNF530's activity if it is regulated by these pathways. Lastly, Triciribine, which inhibits AKT phosphorylation, can lead to a functional inhibition of ZNF530 by blocking essential signaling events requiring AKT.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. ZNF530 is a zinc finger protein that may be involved in DNA binding and transcription regulation. Staurosporine can inhibit kinases that phosphorylate ZNF530, thereby inhibiting its DNA binding capability and transcription regulatory function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases. By inhibiting PI3K, LY294002 can reduce the phosphorylation states of downstream signaling molecules that could regulate the activity of ZNF530 within its signaling context, thus functionally inhibiting ZNF530. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic target of rapamycin). Since mTOR is involved in protein synthesis and cell growth, its inhibition can lead to decreased function of proteins involved in these processes, including ZNF530, by disrupting the processes that are essential for its functional activity within the cell. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1/2, enzymes upstream of ERK in the MAPK pathway. By inhibiting MEK1/2, U0126 can prevent the activation of ERK and potentially inhibit the phosphorylation and activity of ZNF530 if it is regulated by MAPK/ERK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which works similarly to U0126. By inhibiting MEK, PD98059 can block the MAPK/ERK pathway and disrupt the phosphorylation and activity of ZNF530 if it is part of this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase can lead to a decrease in the functional activity of ZNF530 by inhibiting signaling pathways that are essential for its activity, particularly if ZNF530 is involved in stress response pathways regulated by p38 MAPK. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases can phosphorylate a variety of substrates, including proteins like ZNF530, which could be involved in signal transduction pathways. Inhibition by PP2 can thus inhibit the phosphorylation and subsequent activity of ZNF530. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If ZNF530 is involved in the JNK signaling pathway, inhibition of JNK by SP600125 can lead to a decrease in ZNF530's activity by preventing its phosphorylation or by disrupting the signaling pathways that ZNF530 is involved in. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
PD168393 is an irreversible inhibitor of EGFR tyrosine kinase. It can inhibit downstream signaling pathways that may involve ZNF530, leading to the inhibition of its functional activity, especially if ZNF530 is involved in processes regulated by EGFR signaling. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is an inhibitor of Raf-1 kinase, part of the MAPK/ERK pathway. By inhibiting Raf-1, GW5074 can disrupt the MAPK/ERK signaling that may be essential for the activity of ZNF530, particularly if ZNF530 relies on this pathway for its function. | ||||||